Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger, Navin Pinto, Scot Ebbinghaus et al.|The Lancet Oncology|2019

Cited by 341